Logiscreen

Immunovant Inc

$31.11
Market Cap 6.33B
ROE -68.2%
Gross Margin 0.0%
Debt/Equity 0.0
Current Ratio 9.1
Revenue QoQ 0.0%
EPS QoQ 0.2%
F-Score 1

About

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-13.15
vs median 33.61
P/B
7.80
vs median 2.16
ROE
-0.68
vs median 0.09

Lower quality - review fundamentals carefully

Mid-cap company with growth potential

Similar companies

PTGXTGTXLEGNAPGEPCVXSYRE
Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics